Loading…
Immutep Limited is projected to rise to $0.5321 by 2027, a +27% move from its current price of $0.419. IMMP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.4063 | $0.4195 | $0.4331 | +0.11% |
| Jul 14 | $0.4014 | $0.42 | $0.4393 | +0.23% |
| Jul 15 | $0.3978 | $0.4204 | $0.4443 | +0.34% |
| Jul 16 | $0.3949 | $0.4209 | $0.4487 | +0.46% |
| Jul 17 | $0.3924 | $0.4214 | $0.4526 | +0.57% |
| Jul 18 | $0.3901 | $0.4219 | $0.4562 | +0.68% |
| Jul 19 | $0.3881 | $0.4223 | $0.4596 | +0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3881 | $0.4223 | $0.4596 | +0.80% |
| Week 2 | $0.3778 | $0.4257 | $0.4797 | +1.61% |
| Week 3 | $0.3707 | $0.4291 | $0.4967 | +2.42% |
| Week 4 | $0.3653 | $0.4326 | $0.5122 | +3.24% |
| Week 5 | $0.361 | $0.436 | $0.5267 | +4.06% |
| Week 6 | $0.3574 | $0.4395 | $0.5405 | +4.89% |
| Week 7 | $0.3543 | $0.443 | $0.554 | +5.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immutep Limited is a biotechnology company focused on developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
The company’s pipeline includes multiple programs such as TACTI-004 (phase III for first line non-small cell lung cancer), TACTI-003 (phase IIb for first line head and neck squamous cell carcinoma), INSIGHT-005 (phase I for metastatic urothelial carcinoma), TACTI-002 (phase II for NSCLC and HNSCC), AIPAC-003 (phase II/III for metastatic breast cancer), EFTISARC-NEO (phase II for soft tissue sarcoma), INSIGHT-003 (phase I for 1L NSCLC), INSIGHT-005 (phase I for metastatic urothelial cancer), IMP761 (phase I for autoimmune disease), IMP731 for oncology and autoimmune diseases, and LAG525. Immutep collaborates with Merck & Co., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. Formerly known as Prima BioMed Ltd, the company changed its name to Immutep Limited in November 2017.
It was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited (IMMP) is a biotechnology company focused on LAG-3 related immunotherapies. The current price is $0.4424 with a market cap of $65.2M and a rank of 4387.
The stock sits within a price environment shaped by a 30-day technical range and a bullish longer-term outlook supported by a multi-year forecast showing upside potential. The 30-day range is $0.3534 to $0.5539, and near-term technical levels include a support at $0.36 and a resistance at $0.49.
The overall outlook suggests bullish momentum over the coming years, with average price forecasts rising from the mid-2020s into the 2030s and beyond, including notable long-range milestones.
A major floor 26.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.1% below — buyers have tended to step in here.
The nearest ceiling, 7.4% above — a clean break opens room to run.
A major ceiling 558.7% above — clearing it would confirm fresh momentum.
Key IMMP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMMP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.432 | Sell | $0.4252 | Sell |
| MA 10 | $0.423 | Sell | $0.4205 | Sell |
| MA 20 | $0.3995 | Buy | $0.4144 | Buy |
| MA 50 | $0.4248 | Sell | $0.5057 | Sell |
| MA 100 | $0.8488 | Sell | $0.8341 | Sell |
| MA 200 | $1.58 | Sell | $1.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.22 | Neutral |
| Stoch RSI (14) | 54.75 | Neutral |
| CCI (20) | 53.59 | Neutral |
| Williams %R (14) | -42.86 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.69 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 57.14 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 53.76 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 0.43 | Sell |
| ADX (14) | 15.54 | Neutral |
| ATR (14) | 0.01 | Info |
The near-term technical picture is labeled bullish. The RSI14 is 60, placing momentum in a neutral-to-bullish zone, with the price hovering around the 50-day and far from the 200-day moving average. The 50-day simple moving average sits at $0.4334, while the 200-day moving average stands at $1.61, indicating a broader upward bias if the price can close above the shorter-term trend.
In the next 30 days, the stock trades within a range of $0.3534 to $0.5539, suggesting limited downside protection near the $0.36 support and a near-term ceiling near $0.49 resistance. Market activity could test these levels as traders weigh news flow and broader biotech volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.31 | $0.419 | $0.6248 | 0% | Neutral | |
| $0.4169 | $0.5321 | $0.7224 | +27% | Bullish | |
| $0.4298 | $0.567 | $0.803 | +35% | Bullish | |
| $0.4138 | $0.5612 | $0.8212 | +34% | Bullish | |
| $0.3922 | $0.5452 | $0.8201 | +30% | Bullish | |
| $0.378 | $0.5373 | $0.8278 | +28% | Bullish | |
| $0.4318 | $0.6268 | $0.9867 | +50% | Bullish | |
| $0.5192 | $0.7688 | $1.23 | +83% | Bullish | |
| $0.5006 | $0.7553 | $1.23 | +80% | Bullish | |
| $0.49 | $0.7528 | $1.25 | +80% | Bullish | |
| $0.6195 | $1.03 | $1.84 | +147% | Bullish | |
| $0.8472 | $1.64 | $3.21 | +290% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.31 | $0.419 | $0.5051 | +0.00% |
| August 2026 | $0.3776 | $0.4479 | $0.5469 | +6.89% |
| September 2026 | $0.3887 | $0.4648 | $0.5749 | +3.78% |
| October 2026 | $0.3818 | $0.4597 | $0.5749 | -1.09% |
| November 2026 | $0.387 | $0.4688 | $0.5915 | +1.97% |
| December 2026 | $0.4032 | $0.4911 | $0.6248 | +4.76% |
Click any year to see its month-by-month IMMP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMMP could reach as high as $0.6248, with a base case around $0.419 and support toward $0.31 — roughly 0% from $0.419. Price action looks broadly range-bound.
Expect IMMP to range from $0.4169 to $0.7224 through 2027. The $0.5321 average target implies a +27% move from current prices. That is up +27% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMMP price prediction for 2028 points to an average of $0.567 (low $0.4298, high $0.803) — a potential gain of +35% on today's $0.419. Momentum favours further upside here.
In 2029, IMMP is projected to trade between $0.4138 and $0.8212, averaging $0.5612 — a potential gain of +34% from today's $0.419. That is -1% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Immutep Limited's 2030 outlook centres on $0.5452, within a $0.3922 to $0.8201 range. That is -3% versus the projected 2029 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2031, IMMP could reach as high as $0.8278, with a base case around $0.5373 and support toward $0.378 — roughly +28% from $0.419. Buyers look set to stay in control over this stretch.
Expect IMMP to range from $0.4318 to $0.9867 through 2032. The $0.6268 average target implies a +50% move from current prices. That is up +17% on the projected 2031 average. Momentum favours further upside here.
The IMMP price prediction for 2033 points to an average of $0.7688 (low $0.5192, high $1.23) — a potential gain of +83% on today's $0.419. Buyers look set to stay in control over this stretch.
In 2034, IMMP is projected to trade between $0.5006 and $1.23, averaging $0.7553 — a potential gain of +80% from today's $0.419. That is -2% versus the projected 2033 average. Momentum favours further upside here.
Immutep Limited's 2035 outlook centres on $0.7528, within a $0.49 to $1.25 range. That is 0% versus the projected 2034 average. That marks a +80% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMMP could reach as high as $1.84, with a base case around $1.03 and support toward $0.6195 — roughly +147% from $0.419. Momentum favours further upside here.
Expect IMMP to range from $0.8472 to $3.21 through 2050. The $1.64 average target implies a +290% move from current prices. That is up +58% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMMP today (≈ 2,386.634845 IMMP) could be worth
$3,904.45
+$2,904.45 (+290%) by 2050 · US Dollar
Based on the average projected IMMP price of $1.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMMPwould be worth at today's price.
$1,000 invested in IMMP on Jul 10, 2025 (≈ 609.756103 IMMP) would be worth
$255.49
-$744.51 (-74.5%) today · 0.26× · US Dollar
Based on a IMMP entry price of $1.64 vs. today's $0.419.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.42 | $997.62 | -0.2% |
| 1 month ago | $0.36 | $1,163.89 | +16.4% |
| 3 months ago | $0.31 | $1,351.61 | +35.2% |
| 6 months ago | $3.07 | $136.48 | -86.4% |
| 1 year ago | $1.64 | $255.49 | -74.5% |
| All time (5.0y) ago | $3.89 | $107.71 | -89.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMMP forecast.
Our base-case forecast reaches $0.84 around 2040.
Implied market cap at $0.84: $123.79M
The multi-year forecast presents a bullish trajectory with rising price expectations in the coming years. For 2026, the average price is $0.4424 with a target range from $0.31 to $0.6731. By 2027, the average forecast climbs to $0.5654 with a range of $0.4395 to $0.7756 and a 27.8% implied return.
In 2028, the average is $0.6096 and the upper target reaches $0.8743, with a 37.8% upside.
The forecast continues to be upbeat into 2029 and 2030, with 2030 showing an average of $0.5727 and a max of $0.875 (min $0.406), representing a 29.4% upside and bullish sentiment. By 2032 the average is $0.6703 and the max $1.07 (min $0.4534), maintaining a bullish stance into the early 2030s. Notably, 2033/2034/2035 show substantial upside opportunities with max forecasts well above $1.0 and average levels in the $0.8–$1.0 range.
Longer-dated projections show strong upside: by 2040, the average price is forecast at $1.11 with a max of $2.02 and a 151.3% return, and by 2050 the average is $1.74 with a max of $3.51 and a 293.1% return, all under a bullish sentiment. These figures imply meaningful downside protection within the forecast band while highlighting substantial upside risk across the horizon. While these are estimates and not guarantees, the trajectory points to significant longer-term upside potential under the provided scenario.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.5727 with a min of $0.406 and a max of $0.875, and a 29.4% ROI. The sentiment is bullish.
Forecasts indicate bullish sentiment across multiple years, with the average price rising to $1.11 by 2040 and $1.74 by 2050, corresponding to ROIs of 151.3% and 293.1% respectively, though these are estimates and not guarantees.
Yes. The 2033 forecast shows an average of $0.8223 with a max of $1.34, and 2034 shows a max of $1.35. By 2040 the max is $2.02 and by 2050 the max is $3.51.
Current price is $0.4424. The 30-day range is between $0.3534 and $0.5539.
Market cap is $65.2M and the annualized volatility is 70%.
Immutep Limited Community Discussion
0Share your Immutep Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.